Table 1 |
||||||
|
Protein expression changes induced by TGF-β (24 hour treatment) in BRI-JM01 cells, identified by WGA affinity workflow. |
||||||
| BR1 |
BR2 |
BR3 |
||||
| Swiss-Prot |
# pept |
ratio1 ± SD |
# pept |
ratio ± SD |
# pept |
ratio ± SD |
|
|
||||||
| UP-REGULATED |
||||||
| Q06890|CLUS_MOUSE Clusterin precursor |
||||||
| 9 |
4.21 ± 0.51 |
7 |
4.26 ± 0.17 |
3 |
4.25 ± 0.45 |
|
| P11276|FINC_MOUSE Fibronectin precursor (FN) |
||||||
| 7 |
1.85 ± 0.37 |
8 |
1.63 ± 0.69 |
3 |
1.92 ± 0.57 |
|
| P11688|ITA5_MOUSE Integrin alpha-5 |
||||||
| 2 |
1.41 ± 0.21 |
2 |
1.97 ± 0.16 |
1 |
9.93 ± 1.33 |
|
| NP_997551.1| Acid phosphatase, prostate isoform 1 [NP_062781.2] |
||||||
| 1 |
1.40 ± 0.17 |
1 |
1.49 ± 0.21 |
0 |
-- |
|
| O70309|ITB5_MOUSE Integrin beta-5 |
||||||
| 2 |
1.39 ± 0.14 |
2 |
0.99 ± 0.16 |
2 |
1.55 ± 0.10 |
|
| NP_058085.1| Heterogeneous nuclear ribonucleoprotein U |
||||||
| 2 |
1.36 ± 0.6 |
2 |
1.37 ± 0.27 |
0 |
-- |
|
| P63260|ACTG_MOUSE Actin, cytoplasmic 2 [P60710] |
||||||
| 8 |
1.34 ± 0.21 |
10 |
1.13 ± 0.08 |
6 |
1.62 ± 0.08 |
|
| DOWN-REGULATED |
||||||
| Q9QZM0|UBQL2_MOUSE Ubiquilin-2 |
||||||
| 1 |
0.91 ± 0.71 |
3 |
0.69 ± 0.08 |
1 |
0.64 ± 0.16 |
|
| Q8R143|PTTG_MOUSE Pituitary tumor-transforming gene 1 |
||||||
| 2 |
0.80 ± 0.05 |
2 |
0.70 ± 0.04 |
0 |
-- |
|
| P35951|LDLR_MOUSE Low-density lipoprotein receptor precursor |
||||||
| 1 |
0.62 ± 0.11 |
1 |
0.71 ± 0.06 |
0 |
-- |
|
| Q61739|ITA6_MOUSE Integrin alpha-6 |
||||||
| 13 |
0.57 ± 0.08 |
13 |
0.79 ± 0.04 |
4 |
0.87 ± 0.03 |
|
| NP_598424.2| Integrin beta 4 |
||||||
| 15 |
0.56 ± 0.08 |
15 |
0.84 ± 0.05 |
3 |
0.98 ± 0.22 |
|
| NP_064431.2| tumor-associated calcium signal transducer 2 |
||||||
| 2 |
0.51 ± 0.12 |
2 |
0.57 ± 0.05 |
0 |
-- |
|
|
1abundance in TGF-β/abundance in CTL | ||||||
Hill et al. Proteome Science 2009 7:2 doi:10.1186/1477-5956-7-2 |
||||||
